Safety Information

• The most common adverse reactions associated with IMOGAM Rabies–HT Immune Globulin are usually mild and may include tenderness, pain, soreness, and muscle stiffness at the injection site; headache and malaise (a vague feeling of bodily discomfort) may also occur^1-3

• IMOGAM Rabies-HT Immune Globulin is made from human plasma. Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, although prescreening of donors and extensive testing are intended to minimize the risk.

• IMOGAM Rabies–HT Immune Globulin should NOT be given in repeated doses once post-exposure treatment has been started because it may interfere with the immune response to the rabies vaccine^1,2

• IMOGAM Rabies–HT Immune Globulin should be given with caution to anyone who has had a prior allergic reaction following the administration of human immune globulin²

• IMOGAM Rabies–HT Immune Globulin contains trace amounts of neomycin; while the risk of allergic reaction is small, it should be given with caution to persons with known hypersensitivities to antibiotics²

• Although serious adverse reactions to IMOGAM Rabies–HT Immune Globul are very rare, they should be reported to the Vaccine Adverse Event Reporting System (VAERS) via the 24-hour toll-free telephone number (800-822-7967) or on-line at: https://secure.vaers.org/VaersDataEntryintro.htm

• When administering an intramuscular injection, like IMOGAM Rabies–HT immune globulin, in people with bleeding disorders, caution should be exercised because they may develop a serious bruise or collection of blood at the injection site.

For more information about IMOVAX Rabies vaccine and IMOGAM Rabies–HT Immune Globulin, please talk to your health-care professional.

View full Prescribing Information for IMOGAM Rabies–HT Immune Globulin.

References: 1. Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-21. 2. IMOGAM Rabies–HT Prescribing Information, November 2000. 3. Lang J, Gravenstein S, Briggs D, et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals. 1998;26:7-15.